Is Combination Antiviral Therapy Mandatory for Maintenance Therapy in Fully Suppressed Multidrug-Resistant Hepatitis B Patients?
Table 3
Univariable Cox proportional hazard analysis for LC development.
Parameter
Univariable analysis
HR (95% CI)
value
Treatment
Combination group
1 (reference)
Single group
3.06 (0.28–32.35)
0.35
Age (per year)
1.04 (0.94–1.14)
0.44
Male
0.31 (0.06–1.54)
0.15
HBeAg
Negative
1 (reference)
Positive
2.92 (0.34–25.02)
0.32
AST (per 1 IU/L)
1.02 (0.93–1.12)
0.69
ALT (per 1 IU/L)
1.02 (0.98–1.06)
0.27
rtA181 mutation
Absent
1 (reference)
Present
0.35 (0.04–3.00)
0.34
rtA181 and rtN236 mutation
Absent
1 (reference)
Present
1.06 (0.05–23.64)
0.97
Virologic breakthrough
Absent
1 (reference)
Present
4.88 (0.12–207.22)
0.41
Minor virologic breakthrough
Absent
1 (reference)
Present
0.40 (0.02–9.64)
0.57
Time-varying Cox was applied for analysis. Virologic breakthrough was defined as HBV DNA. Minor virologic breakthrough was defined as HBV DNA . ALT: alanine aminotransferase; AST: aspartate aminotransferase; CI: confidence interval; HBV: hepatitis B virus; HR: hazard ratio; LC: liver cirrhosis.
